202 related articles for article (PubMed ID: 20732972)
1. α6ß2* and α4ß2* nicotinic receptors both regulate dopamine signaling with increased nigrostriatal damage: relevance to Parkinson's disease.
Perez XA; Bordia T; McIntosh JM; Quik M
Mol Pharmacol; 2010 Nov; 78(5):971-80. PubMed ID: 20732972
[TBL] [Abstract][Full Text] [Related]
2. Nigrostriatal damage preferentially decreases a subpopulation of alpha6beta2* nAChRs in mouse, monkey, and Parkinson's disease striatum.
Bordia T; Grady SR; McIntosh JM; Quik M
Mol Pharmacol; 2007 Jul; 72(1):52-61. PubMed ID: 17409284
[TBL] [Abstract][Full Text] [Related]
3. Decrease in alpha3*/alpha6* nicotinic receptors but not nicotine-evoked dopamine release in monkey brain after nigrostriatal damage.
McCallum SE; Parameswaran N; Bordia T; McIntosh JM; Grady SR; Quik M
Mol Pharmacol; 2005 Sep; 68(3):737-46. PubMed ID: 15933214
[TBL] [Abstract][Full Text] [Related]
4. Nicotine partially protects against paraquat-induced nigrostriatal damage in mice; link to alpha6beta2* nAChRs.
Khwaja M; McCormack A; McIntosh JM; Di Monte DA; Quik M
J Neurochem; 2007 Jan; 100(1):180-90. PubMed ID: 17227438
[TBL] [Abstract][Full Text] [Related]
5. α4β2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats.
Quik M; Campos C; Bordia T; Strachan JP; Zhang J; McIntosh JM; Letchworth S; Jordan K
Neuropharmacology; 2013 Aug; 71():191-203. PubMed ID: 23583932
[TBL] [Abstract][Full Text] [Related]
6. α6β2*-subtype nicotinic acetylcholine receptors are more sensitive than α4β2*-subtype receptors to regulation by chronic nicotine administration.
Marks MJ; Grady SR; Salminen O; Paley MA; Wageman CR; McIntosh JM; Whiteaker P
J Neurochem; 2014 Jul; 130(2):185-98. PubMed ID: 24661093
[TBL] [Abstract][Full Text] [Related]
7. Selective recovery of striatal 125I-alpha-conotoxinmii nicotinic receptors after nigrostriatal damage in monkeys.
Lai A; Sum J; Fan H; McIntosh JM; Quik M
Neuroscience; 2004; 127(2):399-408. PubMed ID: 15262330
[TBL] [Abstract][Full Text] [Related]
8. Nicotine is neuroprotective when administered before but not after nigrostriatal damage in rats and monkeys.
Huang LZ; Parameswaran N; Bordia T; Michael McIntosh J; Quik M
J Neurochem; 2009 May; 109(3):826-37. PubMed ID: 19250334
[TBL] [Abstract][Full Text] [Related]
9. Characterization of AN6001, a positive allosteric modulator of α6β2-containing nicotinic acetylcholine receptors.
van Hout M; Klein J; Ahring PK; Brown DT; Thaneshwaran S; Dos Santos AB; Jensen AA; Kohlmeier KA; Christophersen P; Dyhring T
Biochem Pharmacol; 2020 Apr; 174():113788. PubMed ID: 31887290
[TBL] [Abstract][Full Text] [Related]
10. Varenicline is a potent partial agonist at α6β2* nicotinic acetylcholine receptors in rat and monkey striatum.
Bordia T; Hrachova M; Chin M; McIntosh JM; Quik M
J Pharmacol Exp Ther; 2012 Aug; 342(2):327-34. PubMed ID: 22550286
[TBL] [Abstract][Full Text] [Related]
11. Vulnerability of 125I-alpha-conotoxin MII binding sites to nigrostriatal damage in monkey.
Quik M; Polonskaya Y; Kulak JM; McIntosh JM
J Neurosci; 2001 Aug; 21(15):5494-500. PubMed ID: 11466420
[TBL] [Abstract][Full Text] [Related]
12. Cotinine selectively activates a subpopulation of alpha3/alpha6beta2 nicotinic receptors in monkey striatum.
O'Leary K; Parameswaran N; McIntosh JM; Quik M
J Pharmacol Exp Ther; 2008 May; 325(2):646-54. PubMed ID: 18305015
[TBL] [Abstract][Full Text] [Related]
13. Long-term nicotine treatment differentially regulates striatal alpha6alpha4beta2* and alpha6(nonalpha4)beta2* nAChR expression and function.
Perez XA; Bordia T; McIntosh JM; Grady SR; Quik M
Mol Pharmacol; 2008 Sep; 74(3):844-53. PubMed ID: 18583454
[TBL] [Abstract][Full Text] [Related]
14. Characterization of AN317, a novel selective agonist of α6β2-containing nicotinic acetylcholine receptors.
Sandager-Nielsen K; Ahring PK; Klein J; van Hout M; Thaneshwaran S; Dos Santos AB; Jacobsen TA; Amrutkar DV; Peters D; Jensen AA; Kohlmeier KA; Christophersen P; Dyhring T
Biochem Pharmacol; 2020 Apr; 174():113786. PubMed ID: 31887288
[TBL] [Abstract][Full Text] [Related]
15. Partial recovery of striatal nicotinic receptors in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned monkeys with chronic oral nicotine.
Bordia T; Parameswaran N; Fan H; Langston JW; McIntosh JM; Quik M
J Pharmacol Exp Ther; 2006 Oct; 319(1):285-92. PubMed ID: 16837557
[TBL] [Abstract][Full Text] [Related]
16. Multiple roles for nicotine in Parkinson's disease.
Quik M; Huang LZ; Parameswaran N; Bordia T; Campos C; Perez XA
Biochem Pharmacol; 2009 Oct; 78(7):677-85. PubMed ID: 19433069
[TBL] [Abstract][Full Text] [Related]
17. Differential declines in striatal nicotinic receptor subtype function after nigrostriatal damage in mice.
Quik M; Sum JD; Whiteaker P; McCallum SE; Marks MJ; Musachio J; McIntosh JM; Collins AC; Grady SR
Mol Pharmacol; 2003 May; 63(5):1169-79. PubMed ID: 12695545
[TBL] [Abstract][Full Text] [Related]
18. Long-term nicotine treatment down-regulates α6β2* nicotinic receptor expression and function in nucleus accumbens.
Perez XA; McIntosh JM; Quik M
J Neurochem; 2013 Dec; 127(6):762-71. PubMed ID: 23992036
[TBL] [Abstract][Full Text] [Related]
19. Prominent role of alpha3/alpha6beta2* nAChRs in regulating evoked dopamine release in primate putamen: effect of long-term nicotine treatment.
Perez XA; O'Leary KT; Parameswaran N; McIntosh JM; Quik M
Mol Pharmacol; 2009 Apr; 75(4):938-46. PubMed ID: 19144785
[TBL] [Abstract][Full Text] [Related]
20. Ventral tegmental area α6β2 nicotinic acetylcholine receptors modulate phasic dopamine release in the nucleus accumbens core.
Wickham R; Solecki W; Rathbun L; McIntosh JM; Addy NA
Psychopharmacology (Berl); 2013 Sep; 229(1):73-82. PubMed ID: 23624852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
